Previsioni

Il prezzo obiettivo medio degli analisti è +76,11€ (−0,44%). La mediana è +83,24€ (+8,88%).

Acquista	10
Mantieni	12
Vendi	0

Notizie Vai al feed delle notizie

Merus rises to record high of 96.95 USD after acquisition by Genmab

Merus shares hit an all-time high of 96.95 USD, trading up 130.25% year-to-date and showing a 1-year gain of 115.81%; the RSI indicates overbought conditions. Genmab completed the acquisition of Merus for 6.9 billion USD, purchasing about 94.2% of the common shares at 97.00 USD per share, prompting changes in leadership. Merus reported promising Phase‑2 interim results for the bispecific antibody petosemtamab in left‑sided mCRC, while the company was unprofitable over the past twelve months. Analysts remain cautious: BMO confirms “Market Perform” with a 97 USD price target, and InvestingPro currently rates the stock as overvalued. » Altro su de.investing.com
Merus reaches all-time high at $96.29 after strong price gains and positive study data

Merus stock rose to a record high of $96.29 and is slightly above its 52-week high. The share price has recently recovered markedly (+115.3% over the past year, +128.6% year-to-date) valuing the biotech at about $7.3 billion. Merus reported promising interim results from the phase‑2 trial of petosemtamab with a 100% response rate in left-sided mCRC in first-line therapy. Genmab has announced a cash takeover offer of $97.00 per share; BMO maintains its Market Perform rating with a $97.00 target. » Altro su de.investing.com
Merus reaches all-time high of $96.1 after strong study data

Merus shares rose to an all-time high of $96.1 and are up about 93.35% year to date. The biotechnology company reports solid liquidity (current ratio 7.97) and revenue growth of 57.54%, but is not yet profitable. Attention centers on promising phase‑2 interim results for petosemtamab, including a 100% response rate in first‑line treatment of left‑sided metastatic colorectal cancer. Parallelly, Genmab announced a cash offer of $97.00 per share; Merus plans to present additional study data at an upcoming scientific conference. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2022, MERUS N.V. EO -,09 ha già distribuito 0,0761€ di dividendi. L'ultimo pagamento è avvenuto a marzo 2022.

Dati finanziari dell'azienda

Nell'ultimo trimestre, MERUS N.V. EO -,09 ha registrato ricavi pari a 10,35M€ e un utile netto di −81,40M€

(EUR)	set 2025	YoY
Ricavi	+10,35M	-
Utile lordo	+9,81M	-
Utile netto	−81,40M	-
EBITDA	−64,80M	-

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+5,86Mld€
Numero di azioni	75,84M
Massimo/minimo a 52 settimane	+83,36€ - +28,48€
Dividendi	No
Beta	1,06
Rapporto P/E	−18,40
Rapporto PEG	+0,45
Rapporto P/B	+10,29
Rapporto P/S	+154,68

Profilo aziendale

Merus N.V., ein in der klinischen Phase befindliches Immuno-Onkologie-Unternehmen, erforscht und entwickelt in den Niederlanden bispezifische Antikörpertherapeutika. Die Pipeline der bispezifischen Antikörperkandidaten umfasst Zenocutuzumab (MCLA-128), das sich in einer klinischen Phase-2-Studie zur Behandlung von Patienten mit metastasierendem Brustkrebs sowie in einer klinischen Phase-1/2-Studie zur Behandlung von soliden Tumoren, die Neuregulin 1 beherbergen, befindet. Das Unternehmen entwickelt außerdem MCLA-158, das sich in einer klinischen Studie der Phase I zur Behandlung solider Tumore befindet; MCLA-145, das sich in einer klinischen Studie der Phase 1 zur Behandlung solider Tumore befindet; MCLA-129, das sich in einer klinischen Studie der Phase 1/2 zur Behandlung von Patienten mit fortgeschrittenem nicht-kleinzelligem Lungenkrebs und anderen soliden Tumoren befindet; und ONO-4685, das sich in einer klinischen Studie der Phase 1 zur Behandlung des rezidivierten/refraktären T-Zell-Lymphoms befindet. Darüber hinaus hat das Unternehmen eine Kooperationsvereinbarung mit Betta Pharmaceuticals Co. Ltd. für die Erforschung und Entwicklung von bispezifischen Antikörperkandidaten, darunter MCLA-129, und eine Zusammenarbeit mit der Incyte Corporation für die Entwicklung von MCLA-145. Das Unternehmen wurde im Jahr 2003 gegründet und hat seinen Hauptsitz in Utrecht, Niederlande.

Nome	MERUS N.V. EO -,09
CEO	Jan van de Winkel
Sede centrale	Utrecht, Israele
Sito web	merus.nl
Settore	Servizi di pubblica utilità
Industria	Prodotti chimici
Quotazione in borsa	26/04/2019
Dipendenti	260